Skill Tracer
Skills › Scientific Agent Skills › peer-review › common_issues.md

common_issues.md

257 lines · skills/peer-review/references/common_issues.md at 5f2bc03

Open on GitHub

Most marks come from matching words in the file, so treat them as pointers.

1# Common Issues in Manuscript Review
2
3Use this reference as a prompt for inquiry, not a defect checklist. A possible issue becomes a review comment only when it is relevant to the study and supported by a manuscript location, supplied artifact, or applicable method principle.
4
5Do not infer misconduct, poor quality, or manuscript merit from a missing reporting item. Separate:
6
7- **Not reported:** the manuscript does not provide enough information to assess the point.
8- **Potential design or analysis problem:** the reported method may not answer the stated question.
9- **Demonstrated inconsistency:** two supplied artifacts or manuscript locations conflict.
10- **Integrity concern:** credible evidence should be described neutrally and routed through the journal process, normally in confidential editor notes.

Common Issues in Manuscript Review

Use this reference as a prompt for inquiry, not a defect checklist. A possible issue becomes a review comment only when it is relevant to the study and supported by a manuscript location, supplied artifact, or applicable method principle.

Do not infer misconduct, poor quality, or manuscript merit from a missing reporting item. Separate:

  • Not reported: the manuscript does not provide enough information to assess the point.
  • Potential design or analysis problem: the reported method may not answer the stated question.
  • Demonstrated inconsistency: two supplied artifacts or manuscript locations conflict.
  • Integrity concern: credible evidence should be described neutrally and routed through the journal process, normally in confidential editor notes.
Raw lines 1 to 11
12## Claim–evidence alignment
14Check each central claim against the design, analysis, result, and uncertainty that support it.
16Common mismatches:
18- Causal wording from an observational or otherwise non-identifying design
19- Mechanistic conclusions supported only by association or prediction
20- Conclusions based on a secondary, exploratory, or post hoc outcome without labeling
21- Directionally correct claims that overstate magnitude or precision
22- Population, setting, intervention, comparator, outcome, or time-horizon extrapolation
23- “No effect,” “equivalent,” or “safe” conclusions from imprecise or non-significant results
24- Abstract or conclusion claims that omit material harms, uncertainty, subgroup caveats, or null findings
25- Novelty claims that are broader than the search or cited literature supports
27Constructive response:
291. Identify the claim and its location.
302. Identify the relevant result or missing evidence.
313. Explain the alignment problem.
324. Request a bounded remedy: narrow wording, add uncertainty, clarify exploratory status, provide the prespecified analysis, or justify the inference.
34Use `scripts/validate_claim_evidence.py` for a local identifier-based matrix. Its report never echoes claim text.

Claim–evidence alignment

Check each central claim against the design, analysis, result, and uncertainty that support it.

Common mismatches:

  • Causal wording from an observational or otherwise non-identifying design
  • Mechanistic conclusions supported only by association or prediction
  • Conclusions based on a secondary, exploratory, or post hoc outcome without labeling
  • Directionally correct claims that overstate magnitude or precision
  • Population, setting, intervention, comparator, outcome, or time-horizon extrapolation
  • “No effect,” “equivalent,” or “safe” conclusions from imprecise or non-significant results
  • Abstract or conclusion claims that omit material harms, uncertainty, subgroup caveats, or null findings
  • Novelty claims that are broader than the search or cited literature supports

Constructive response:

  1. Identify the claim and its location.
  2. Identify the relevant result or missing evidence.
  3. Explain the alignment problem.
  4. Request a bounded remedy: narrow wording, add uncertainty, clarify exploratory status, provide the prespecified analysis, or justify the inference.

Use scripts/validate_claim_evidence.py for a local identifier-based matrix. Its report never echoes claim text.

Raw lines 12 to 35
Runs code scripts/validate_claim_evidence.py :34
36## Study question, design, and units

Study question, design, and units

Raw lines 36 to 37
38### Question–design mismatch
40Check whether the population, intervention or exposure, comparator, outcomes, timing, and target quantity align from objectives through interpretation. For trials, identify the estimand when relevant. For prediction, distinguish model development from performance evaluation. For diagnostic studies, distinguish diagnostic accuracy from clinical utility.

Question–design mismatch

Check whether the population, intervention or exposure, comparator, outcomes, timing, and target quantity align from objectives through interpretation. For trials, identify the estimand when relevant. For prediction, distinguish model development from performance evaluation. For diagnostic studies, distinguish diagnostic accuracy from clinical utility.

Raw lines 38 to 41
42### Experimental or observational unit
44Potential issues include:
46- Technical replicates treated as independent biological units
47- Multiple cells, images, lesions, eyes, visits, or samples per subject analyzed as independent
48- Cluster assignment analyzed at the individual level without accounting for clustering
49- Paired or repeated observations analyzed as unpaired
50- Site, operator, batch, family, spatial, or temporal dependence ignored
52Request a clear definition of the unit, nesting, repeated measures, and analysis that reflects dependence. Do not assume a mixed model is always the correct remedy; the model must match the design and question.

Experimental or observational unit

Potential issues include:

  • Technical replicates treated as independent biological units
  • Multiple cells, images, lesions, eyes, visits, or samples per subject analyzed as independent
  • Cluster assignment analyzed at the individual level without accounting for clustering
  • Paired or repeated observations analyzed as unpaired
  • Site, operator, batch, family, spatial, or temporal dependence ignored

Request a clear definition of the unit, nesting, repeated measures, and analysis that reflects dependence. Do not assume a mixed model is always the correct remedy; the model must match the design and question.

Raw lines 42 to 53
54### Selection, allocation, and masking
56Assess, as applicable:
58- Sampling frame, recruitment, eligibility, and exclusions
59- Sequence generation and allocation concealment
60- Prospective stopping rules
61- Blinding or masking of participants, personnel, outcome assessors, and analysts
62- Consequences and mitigation when masking is infeasible
63- Baseline measurement timing and post-allocation exclusions
65Avoid treating baseline significance tests as proof of successful randomization. Focus on chance imbalance, clinically important imbalance, prespecified adjustment, and departures from the randomized comparison.

Selection, allocation, and masking

Assess, as applicable:

  • Sampling frame, recruitment, eligibility, and exclusions
  • Sequence generation and allocation concealment
  • Prospective stopping rules
  • Blinding or masking of participants, personnel, outcome assessors, and analysts
  • Consequences and mitigation when masking is infeasible
  • Baseline measurement timing and post-allocation exclusions

Avoid treating baseline significance tests as proof of successful randomization. Focus on chance imbalance, clinically important imbalance, prespecified adjustment, and departures from the randomized comparison.

Raw lines 54 to 66
67### Confounding and causal identification
69For causal claims, ask:
71- What target causal contrast is intended?
72- Which assumptions connect the design and analysis to that contrast?
73- Were confounders selected using subject-matter reasoning rather than outcome-driven screening?
74- Could adjustment introduce collider or mediator bias?
75- Are time-varying treatment, censoring, immortal time, or informative observation processes relevant?
76- Are negative controls, sensitivity analyses, or alternative explanations appropriate?
78Do not demand a specific causal method without showing why it fits the data-generating process.

Confounding and causal identification

For causal claims, ask:

  • What target causal contrast is intended?
  • Which assumptions connect the design and analysis to that contrast?
  • Were confounders selected using subject-matter reasoning rather than outcome-driven screening?
  • Could adjustment introduce collider or mediator bias?
  • Are time-varying treatment, censoring, immortal time, or informative observation processes relevant?
  • Are negative controls, sensitivity analyses, or alternative explanations appropriate?

Do not demand a specific causal method without showing why it fits the data-generating process.

Raw lines 67 to 79
80## Sample size, precision, and replication
82Avoid fixed heuristics such as “n < 30 is too small” or “three replicates are sufficient.” Adequacy depends on the target effect or precision, variability, design effect, event count, model complexity, multiplicity, attrition, and decision context.
84Check:
86- Prospective rationale for sample size or precision
87- Inputs, assumptions, software or method, and allowance for attrition or clustering
88- Whether the primary outcome and analysis match the calculation
89- Event and outcome information relative to model complexity
90- Effective sample size after dependence, missingness, weighting, or splitting
91- Independent biological replication and validation where the claim requires it
92- Precision of estimates, not only nominal power
94Observed or post hoc power calculated from the observed effect generally adds little beyond the estimate and its interval. Request effect estimates and uncertainty rather than “achieved power.”

Sample size, precision, and replication

Avoid fixed heuristics such as “n < 30 is too small” or “three replicates are sufficient.” Adequacy depends on the target effect or precision, variability, design effect, event count, model complexity, multiplicity, attrition, and decision context.

Check:

  • Prospective rationale for sample size or precision
  • Inputs, assumptions, software or method, and allowance for attrition or clustering
  • Whether the primary outcome and analysis match the calculation
  • Event and outcome information relative to model complexity
  • Effective sample size after dependence, missingness, weighting, or splitting
  • Independent biological replication and validation where the claim requires it
  • Precision of estimates, not only nominal power

Observed or post hoc power calculated from the observed effect generally adds little beyond the estimate and its interval. Request effect estimates and uncertainty rather than “achieved power.”

Raw lines 80 to 95
96## Statistical analysis

Statistical analysis

Raw lines 96 to 97
98### Analysis–design alignment
100Check whether the analysis respects:
102- Outcome scale and distribution
103- Pairing, clustering, repeated measures, censoring, and competing events
104- Sampling design, weights, matching, stratification, or blocking
105- Outcome hierarchy and prespecified estimand
106- Non-inferiority or equivalence margins and analysis populations
107- Longitudinal timing and informative dropout
109Do not prescribe “parametric” or “non-parametric” methods from sample size alone.

Analysis–design alignment

Check whether the analysis respects:

  • Outcome scale and distribution
  • Pairing, clustering, repeated measures, censoring, and competing events
  • Sampling design, weights, matching, stratification, or blocking
  • Outcome hierarchy and prespecified estimand
  • Non-inferiority or equivalence margins and analysis populations
  • Longitudinal timing and informative dropout

Do not prescribe “parametric” or “non-parametric” methods from sample size alone.

Raw lines 98 to 110
111### Assumptions and diagnostics
113The relevant assumptions depend on the estimand and model. A standalone normality test is not a universal gatekeeper and can be uninformative in very small or large samples. Look for design-aware diagnostics, residual behavior, influential observations, functional form, calibration, proportional hazards where applicable, and sensitivity to reasonable alternatives.
115Comments should identify the assumption at risk and why it matters. “Check normality” without specifying the modeled quantity or consequence is not actionable.

Assumptions and diagnostics

The relevant assumptions depend on the estimand and model. A standalone normality test is not a universal gatekeeper and can be uninformative in very small or large samples. Look for design-aware diagnostics, residual behavior, influential observations, functional form, calibration, proportional hazards where applicable, and sensitivity to reasonable alternatives.

Comments should identify the assumption at risk and why it matters. “Check normality” without specifying the modeled quantity or consequence is not actionable.

Raw lines 111 to 116
117### Effect estimates and uncertainty
119Flag:
121- Thresholded interpretation of p-values
122- P-values used as effect size, importance, or probability that a hypothesis is true
123- “Significant” versus “not significant” used as evidence of a difference between effects
124- Missing effect estimates, compatible intervals, denominators, or units
125- Excessive precision or inconsistent rounding
126- Confidence, credible, or prediction intervals described incorrectly
127- Clinical or practical importance conflated with statistical compatibility
129Prefer estimates, uncertainty, assumptions, and context. The ASA p-value principles and SAMPL reporting guidance are indexed in `assets/source_ledger.csv`.

Effect estimates and uncertainty

Flag:

  • Thresholded interpretation of p-values
  • P-values used as effect size, importance, or probability that a hypothesis is true
  • “Significant” versus “not significant” used as evidence of a difference between effects
  • Missing effect estimates, compatible intervals, denominators, or units
  • Excessive precision or inconsistent rounding
  • Confidence, credible, or prediction intervals described incorrectly
  • Clinical or practical importance conflated with statistical compatibility

Prefer estimates, uncertainty, assumptions, and context. The ASA p-value principles and SAMPL reporting guidance are indexed in assets/source_ledger.csv.

Raw lines 117 to 130
131### Multiplicity and analysis flexibility
133Assess:
135- Number and hierarchy of outcomes, time points, subgroups, contrasts, and models
136- Interim looks, adaptive changes, or repeated data inspection
137- Family or false-discovery control when required by the inferential aim
138- Transparent labeling of confirmatory and exploratory analyses
139- Consistency with protocol, registration, and statistical analysis plan
140- Complete reporting rather than selective presentation of favorable analyses
142Not every collection of analyses requires the same correction. Ask authors to state the inferential family and rationale instead of automatically demanding Bonferroni adjustment.

Multiplicity and analysis flexibility

Assess:

  • Number and hierarchy of outcomes, time points, subgroups, contrasts, and models
  • Interim looks, adaptive changes, or repeated data inspection
  • Family or false-discovery control when required by the inferential aim
  • Transparent labeling of confirmatory and exploratory analyses
  • Consistency with protocol, registration, and statistical analysis plan
  • Complete reporting rather than selective presentation of favorable analyses

Not every collection of analyses requires the same correction. Ask authors to state the inferential family and rationale instead of automatically demanding Bonferroni adjustment.

Raw lines 131 to 143
144### Missing data and intercurrent events
146Check:
148- Amount and reasons by group and time
149- Distinction between intercurrent events and missing observations when relevant
150- Assumptions behind complete-case, imputation, weighting, likelihood, or other methods
151- Inclusion of variables and uncertainty in multiple imputation
152- Sensitivity analyses to plausible departures from assumptions
153- Alignment between the target quantity, data collection, and missing-data strategy
155Do not require a test that data are “missing completely at random”; missingness assumptions are not generally established by a single diagnostic test.

Missing data and intercurrent events

Check:

  • Amount and reasons by group and time
  • Distinction between intercurrent events and missing observations when relevant
  • Assumptions behind complete-case, imputation, weighting, likelihood, or other methods
  • Inclusion of variables and uncertainty in multiple imputation
  • Sensitivity analyses to plausible departures from assumptions
  • Alignment between the target quantity, data collection, and missing-data strategy

Do not require a test that data are “missing completely at random”; missingness assumptions are not generally established by a single diagnostic test.

Raw lines 144 to 156
157### Outliers, transformations, and limits
159Check whether exclusions, transformations, winsorization, detection-limit handling, and influential-observation rules were prespecified or transparently justified. Request sensitivity analyses when conclusions depend materially on discretionary handling. Do not demand deletion merely because a value is extreme.

Outliers, transformations, and limits

Check whether exclusions, transformations, winsorization, detection-limit handling, and influential-observation rules were prespecified or transparently justified. Request sensitivity analyses when conclusions depend materially on discretionary handling. Do not demand deletion merely because a value is extreme.

Raw lines 157 to 160
161### Subgroups and heterogeneity
163Look for prespecification, adequate interaction analysis, multiplicity, uncertainty, biological or clinical rationale, and consistency of direction. Within-group significance and between-group non-significance do not establish subgroup differences.

Subgroups and heterogeneity

Look for prespecification, adequate interaction analysis, multiplicity, uncertainty, biological or clinical rationale, and consistency of direction. Within-group significance and between-group non-significance do not establish subgroup differences.

Raw lines 161 to 164
165### Prediction and machine learning
167Check:
169- Clear target population, outcome, prediction time, and intended use
170- Separation of training, tuning, and evaluation without leakage
171- Representative evaluation data and transportability
172- Handling of missing values and preprocessing within resampling folds
173- Calibration as well as discrimination when relevant
174- Uncertainty around performance and decision consequences
175- Overfitting, optimism correction, and external evaluation
176- Model and preprocessing availability, versioning, and human oversight
177- Fairness analyses tied to intended use, not demographic metrics without context
179TRIPOD+AI applies to regression and machine-learning prediction models; STARD-AI applies when diagnostic accuracy is the primary evaluation target.

Prediction and machine learning

Check:

  • Clear target population, outcome, prediction time, and intended use
  • Separation of training, tuning, and evaluation without leakage
  • Representative evaluation data and transportability
  • Handling of missing values and preprocessing within resampling folds
  • Calibration as well as discrimination when relevant
  • Uncertainty around performance and decision consequences
  • Overfitting, optimism correction, and external evaluation
  • Model and preprocessing availability, versioning, and human oversight
  • Fairness analyses tied to intended use, not demographic metrics without context

TRIPOD+AI applies to regression and machine-learning prediction models; STARD-AI applies when diagnostic accuracy is the primary evaluation target.

Raw lines 165 to 180
181## Reproducibility and transparency
183Check whether another qualified researcher could understand and, where permissions allow, repeat the work:
185- Protocol, registration, amendments, and analysis plan
186- Data provenance, processing stages, exclusions, and versioned identifiers
187- Reagents, materials, instruments, software, package versions, parameters, and seeds
188- Code, environment or lock file, run order, and computational resources
189- Data, code, model, and material availability statements
190- Repository accession numbers and persistent identifiers
191- Clear, justified restrictions for privacy, consent, security, licensing, or community governance
193“Available on request” is not automatically invalid, and open release is not always ethical or lawful. Evaluate whether the access route is specific, feasible, and consistent with governance.
195Do not claim to have reproduced an analysis unless it was actually run with documented inputs, environment, commands, and outputs.

Reproducibility and transparency

Check whether another qualified researcher could understand and, where permissions allow, repeat the work:

  • Protocol, registration, amendments, and analysis plan
  • Data provenance, processing stages, exclusions, and versioned identifiers
  • Reagents, materials, instruments, software, package versions, parameters, and seeds
  • Code, environment or lock file, run order, and computational resources
  • Data, code, model, and material availability statements
  • Repository accession numbers and persistent identifiers
  • Clear, justified restrictions for privacy, consent, security, licensing, or community governance

“Available on request” is not automatically invalid, and open release is not always ethical or lawful. Evaluate whether the access route is specific, feasible, and consistent with governance.

Do not claim to have reproduced an analysis unless it was actually run with documented inputs, environment, commands, and outputs.

Raw lines 181 to 196
197## Figures, tables, and images
199Assess the supplied artifact directly; do not infer manipulation from low-resolution rendering alone.
201Check:
203- Axes, units, denominators, scales, legends, and uncertainty definitions
204- Individual data or distribution display when summary graphics conceal relevant structure
205- Accessibility and redundant encoding beyond color alone
206- Consistency among text, tables, figures, and supplements
207- Sample sizes and exclusions for each panel or analysis
208- Image acquisition, processing, normalization, scale bars, and representative-image selection
209- Disclosed splicing or adjustments and availability of source images when policy requires
210- Avoidance of deceptive truncation, area/volume encoding, or dual-axis implication
212Possible duplication or manipulation should be documented neutrally by location and referred to the editor under the journal’s image-integrity process. Do not accuse authors of fabrication.

Figures, tables, and images

Assess the supplied artifact directly; do not infer manipulation from low-resolution rendering alone.

Check:

  • Axes, units, denominators, scales, legends, and uncertainty definitions
  • Individual data or distribution display when summary graphics conceal relevant structure
  • Accessibility and redundant encoding beyond color alone
  • Consistency among text, tables, figures, and supplements
  • Sample sizes and exclusions for each panel or analysis
  • Image acquisition, processing, normalization, scale bars, and representative-image selection
  • Disclosed splicing or adjustments and availability of source images when policy requires
  • Avoidance of deceptive truncation, area/volume encoding, or dual-axis implication

Possible duplication or manipulation should be documented neutrally by location and referred to the editor under the journal’s image-integrity process. Do not accuse authors of fabrication.

Raw lines 197 to 213
214## Ethics, welfare, privacy, and integrity
216Check what is applicable:
218- Ethics committee or institutional review and identifiers
219- Consent, assent, waiver, or lawful basis
220- Trial registration and prospective protocol availability
221- Animal welfare, humane endpoints, and relevant ARRIVE items
222- Privacy, identifiability, community governance, and controlled access
223- Funding, sponsor role, author conflicts, and contributor roles
224- Dual-use, biosafety, environmental, or security considerations
225- Prior publication, overlapping reports, and transparent secondary analyses
227If a concern cannot safely be raised with authors, use the confidential editor channel. State the evidence and uncertainty; do not investigate people, contact institutions, or reveal the manuscript outside the authorized process.

Ethics, welfare, privacy, and integrity

Check what is applicable:

  • Ethics committee or institutional review and identifiers
  • Consent, assent, waiver, or lawful basis
  • Trial registration and prospective protocol availability
  • Animal welfare, humane endpoints, and relevant ARRIVE items
  • Privacy, identifiability, community governance, and controlled access
  • Funding, sponsor role, author conflicts, and contributor roles
  • Dual-use, biosafety, environmental, or security considerations
  • Prior publication, overlapping reports, and transparent secondary analyses

If a concern cannot safely be raised with authors, use the confidential editor channel. State the evidence and uncertainty; do not investigate people, contact institutions, or reveal the manuscript outside the authorized process.

Raw lines 214 to 228
229## Citations and references
231Check:
233- Every consequential literature claim has an appropriate source
234- The cited source supports the stated proposition
235- Primary sources are used for methods, data, and policies when available
236- Retracted or corrected work is handled appropriately
237- Contradictory and relevant evidence is represented fairly
238- Self-citation requests are necessary, specific, and not coercive
239- Citation identifiers and reference entries are internally consistent
241The local `scripts/audit_citations.py` checks Pandoc-style keys such as `[@ref-id]` against a CSV. It does not verify source existence or support and must not be described as doing so.

Citations and references

Check:

  • Every consequential literature claim has an appropriate source
  • The cited source supports the stated proposition
  • Primary sources are used for methods, data, and policies when available
  • Retracted or corrected work is handled appropriately
  • Contradictory and relevant evidence is represented fairly
  • Self-citation requests are necessary, specific, and not coercive
  • Citation identifiers and reference entries are internally consistent

The local scripts/audit_citations.py checks Pandoc-style keys such as [@ref-id] against a CSV. It does not verify source existence or support and must not be described as doing so.

Raw lines 229 to 242
Runs code scripts/audit_citations.py :241
243## Writing actionable comments
245For each major or minor comment, include:
247- **Location**
248- **Observation**
249- **Evidence or criterion**
250- **Why it matters**
251- **Requested action**
253Prefer: “At Methods, paragraph 3, the experimental unit is unclear. Because three measurements appear to come from each participant, please define the unit and explain how within-participant dependence was handled.”
255Avoid: “The statistics are bad.”
257Requests for new experiments should be necessary to support an existing central claim, ethically and practically proportionate, and distinguished from optional future work. Often the appropriate remedy is to narrow a claim, add a limitation, provide missing analysis detail, or share an existing artifact.

Writing actionable comments

For each major or minor comment, include:

  • Location
  • Observation
  • Evidence or criterion
  • Why it matters
  • Requested action

Prefer: “At Methods, paragraph 3, the experimental unit is unclear. Because three measurements appear to come from each participant, please define the unit and explain how within-participant dependence was handled.”

Avoid: “The statistics are bad.”

Requests for new experiments should be necessary to support an existing central claim, ethically and practically proportionate, and distinguished from optional future work. Often the appropriate remedy is to narrow a claim, add a limitation, provide missing analysis detail, or share an existing artifact.

Raw lines 243 to 257